Apellis pharmaceuticals, inc. (APLS)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Sep'16
Operating expenses:
Research and development

69,282

78,471

51,319

50,698

40,480

30,805

29,539

27,537

17,402

13,132

9,517

10,422

7,231

6,234

General and administrative

29,504

27,468

18,628

12,778

8,171

6,390

6,265

5,947

4,035

4,859

2,071

1,710

1,821

1,000

Operating loss

-98,786

-105,939

-69,947

-63,476

-48,651

-37,196

-35,804

-33,485

-21,438

-17,992

-11,589

-12,132

-9,052

-7,234

Loss on extinguishment of debt

-

0

-293

-0

-1,208

-

-

-

-

-

-

-

-

-

Loss from remeasurement of development derivative liability

-68,406

-4,736

-263

-9,104

-736

-

-

-

-

-

-

-

-

-

Interest income

2,275

1,478

1,341

1,421

867

914

858

787

400

-

-

-

-

-

Interest expense

3,919

3,930

601

159

593

664

577

603

667

-

-

-

-

-

Interest income (expense), net

-

-

-

-

-

-

-

-

-

-

16

5

10

-

Other income/(expense), net

14

-89

-61

228

-253

61

-22

-32

-31

-150

-0

0

8

23

Net loss

-168,822

-113,217

-69,824

-71,090

-50,574

-36,885

-35,545

-33,334

-21,736

-18,255

-11,573

-12,126

-9,050

-7,210

Other comprehensive gain:
Unrealized gain on marketable securities

1,394

-

-

-

-

-

-

-

-

-

-

-

-

-

Foreign currency gain/ (loss)

-230

51

-83

-1

2

-

-86

-

-

-

-

-

-

-

Total other comprehensive gain/ (loss)

1,164

51

-83

-1

2

-

-86

-

-

-

-

-

-

-

Comprehensive loss, net of tax

-167,658

-113,166

-69,907

-71,091

-50,572

-36,922

-35,632

-33,334

-21,736

-

-11,573

-

-

-

Net loss per common share, basic and diluted

-2.29

-1.81

-1.10

-1.12

-0.87

-0.66

-0.64

-0.61

-0.43

0.20

-1.37

-1.44

-1.07

-0.86

Weighted-average number of common shares used in net loss per common share, basic and diluted

73

121,839

63,752

63,263

57

56,338

56,201

54,691

50,353

30,184

8,442

8,428

8,428

8,428